美股A股
StockGist
Back
6-K2026-04-20· grok-4-1-fast-non-reasoning

AAPG · ASCENTAGE PHARMA GROUP INTERNATIONAL

0001213900-26-045375

SEC filing

Summary

Ascentage Pharma announced four preclinical studies at AACR 2026 demonstrating synergistic potential of olverembatinib, APG-2449, and APG-5918 in combination therapies for endometrial carcinoma, mantle cell lymphoma, BRAF-mutant tumors, and small-cell lung cancer.

Key takeaways